Company / Gross Profit
Corcept Therapeutics Incorporated Gross Profit History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$63.6M
FY2019
5-year range
-
FY2016-FY2019
Trend
+12.6%
vs FY2018
Sector context
#27 of 29
Health Care
What the data says
Among 29 Health Care companies, Corcept Therapeutics Incorporated is in the bottom 7% for gross profit. Gross Profit has increased for 3 consecutive years, from $16M in FY2016 to $64M in FY2019.
Based on SEC 10-K filings.
$64M in FY2019 with a 3-year CAGR of +59.5%.
Improved from $27M to $64M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +59.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 29This company $63.6M Sector average $3.5B
▼
-98.2% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's gross profit has grown for 3 consecutive years.
- 3-year CAGR of +59.5%, indicating consistent growth.
- In FY2019, gross profit increased 12.6% year-over-year.
- Ranks #27 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $63.6M | +12.6% |
| FY2018 | $56.5M | +109.6% |
| FY2017 | $27.0M | +72.1% |
| FY2016 | $15.7M | +59.8% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026